510 related articles for article (PubMed ID: 8727604)
21. Coagulation assays as diagnostic markers of hepatocellular carcinoma.
Lefrère JJ; Conard J; Mavier P; Bettan L; Beaugrand M; Gozin D; Lerable J; Dhumeaux D; Samama M
Thromb Haemost; 1988 Dec; 60(3):468-70. PubMed ID: 2467402
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
24. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
25. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
26. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
29. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
Izuno K; Fujiyama S; Yamasaki K; Sato M; Sato T
Hepatogastroenterology; 1995; 42(4):387-93. PubMed ID: 8586374
[TBL] [Abstract][Full Text] [Related]
30. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
31. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].
Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J
Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243
[TBL] [Abstract][Full Text] [Related]
32. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
33. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
34. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
[TBL] [Abstract][Full Text] [Related]
35. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
36. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
[TBL] [Abstract][Full Text] [Related]
37. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up].
Ishida H; Matsuo S; Inoue Y
Rinsho Byori; 2010 Nov; 58(11):1065-72. PubMed ID: 21229703
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
[TBL] [Abstract][Full Text] [Related]
40. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
